{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:24:42Z","timestamp":1793496282281,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Plasma-to-autopsy studies are essential for validation of blood biomarkers and understanding their relation to Alzheimer\u2019s disease (AD) pathology. Few such studies have been done on phosphorylated tau (p-tau) and those that exist have made limited or no comparison of the different p-tau variants. This study is the first to use immunoprecipitation mass spectrometry (IP-MS) to compare the accuracy of eight different plasma tau species in predicting autopsy-confirmed AD. The sample included 123 participants (AD\u2009=\u200969, non-AD\u2009=\u200954) from the Boston University Alzheimer\u2019s disease Research Center who had an available ante-mortem plasma sample and donated their brain. Plasma samples proximate to death were analyzed by targeted IP-MS for six different tryptic phosphorylated (p-tau-181, 199, 202, 205, 217, 231), and two non-phosphorylated tau (195\u2013205, 212\u2013221) peptides. NIA-Reagan Institute criteria were used for the neuropathological diagnosis of AD. Binary logistic regressions tested the association between each plasma peptide and autopsy-confirmed AD status. Area under the receiver operating curve (AUC) statistics were generated using predicted probabilities from the logistic regression models. Odds Ratio (OR) was used to study associations between the different plasma tau species and CERAD and Braak classifications. All tau species were increased in AD compared to non-AD, but p-tau217, p-tau205 and p-tau231 showed the highest fold-changes. Plasma p-tau217 (AUC\u2009=\u200989.8), p-tau231 (AUC\u2009=\u200983.4), and p-tau205 (AUC\u2009=\u200981.3) all had excellent accuracy in discriminating AD from non-AD brain donors, even among those with CDR\u2009&lt;\u20091). Furthermore, p-tau217, p-tau205 and p-tau231 showed the highest ORs with both CERAD (OR\n                    <jats:sub>p-tau217<\/jats:sub>\n                    \u2009=\u200915.29, OR\n                    <jats:sub>p-tau205<\/jats:sub>\n                    \u2009=\u20095.05 and OR\n                    <jats:sub>p-tau231<\/jats:sub>\n                    \u2009=\u20093.86) and Braak staging (OR\n                    <jats:sub>p-tau217<\/jats:sub>\n                    \u2009=\u200914.29, OR\n                    <jats:sub>p-tau205<\/jats:sub>\n                    \u2009=\u20095.27 and OR\n                    <jats:sub>p-tau231<\/jats:sub>\n                    \u2009=\u20094.02) but presented increased levels at different amyloid and tau stages determined by neuropathological examination. Our findings support plasma p-tau217 as the most promising p-tau species for detecting AD brain pathology. Plasma p-tau231 and p-tau205 may additionally function as markers for different stages of the disease.\n                  <\/jats:p>","DOI":"10.1007\/s00401-023-02660-3","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T05:02:31Z","timestamp":1703912551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Optimal blood tau species for the detection of Alzheimer\u2019s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-6318","authenticated-orcid":false,"given":"Laia","family":"Montoliu-Gaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Alosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eukyung","family":"Yhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorghos","family":"Tripodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sconzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Ally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Gr\u00f6tschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lantero-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo J.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N.","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Simkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine W.","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Budson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoda","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Farrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyungah R.","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil W.","family":"Kowall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee E.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Qiao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand Russell","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor D.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,30]]},"reference":[{"key":"2660_CR1","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS et al (2022) Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med 28:2555\u20132562. https:\/\/doi.org\/10.1038\/s41591-022-02074-w","journal-title":"Nat Med"},{"key":"2660_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141:709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"key":"2660_CR3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20200861","journal-title":"J Exp Med"},{"key":"2660_CR4","first-page":"270","volume":"18","author":"DL Beekly","year":"2004","unstructured":"Beekly DL, Ramos EM, van Belle G, Deitrich W, Clark AD, Jacka ME et al (2004) The national Alzheimer\u2019s coordinating center (NACC) database: an Alzheimer disease database. Alzheimer Dis Assoc Disord 18:270\u2013277","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2660_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/jnen\/nly049","volume":"77","author":"LM Besser","year":"2018","unstructured":"Besser LM, Kukull WA, Teylan MA, Bigio EH, Cairns NJ, Kofler JK et al (2018) The revised national Alzheimer\u2019s coordinating center\u2019s neuropathology form-available data and new analyses. J Neuropathol Exp Neurol 77:717\u2013726. https:\/\/doi.org\/10.1093\/jnen\/nly049","journal-title":"J Neuropathol Exp Neurol"},{"key":"2660_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J et al (2023) A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging 3:1079\u20131090. https:\/\/doi.org\/10.1038\/s43587-023-00471-5","journal-title":"Nat Aging"},{"key":"2660_CR7","first-page":"1","volume":"3","author":"DW Dickson","year":"2009","unstructured":"Dickson DW (2009) Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol 3:1\u201323","journal-title":"Int J Clin Exp Pathol"},{"key":"2660_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/alz.12508","volume":"18","author":"B Frank","year":"2022","unstructured":"Frank B, Ally M, Brekke B, Zetterberg H, Blennow K, Sugarman MA et al (2022) Plasma p-tau(181) shows stronger network association to Alzheimer\u2019s disease dementia than neurofilament light and total tau. Alzheimers Dement 18:1523\u20131536. https:\/\/doi.org\/10.1002\/alz.12508","journal-title":"Alzheimers Dement"},{"key":"2660_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD et al (2022) The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. https:\/\/doi.org\/10.1002\/alz.12756","journal-title":"Alzheimer\u2019s Dementia"},{"key":"2660_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/0471722146","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2000","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX (2000) Applied logistic regression. Wiley"},{"key":"2660_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA Research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"2660_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac333","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E et al (2022) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. https:\/\/doi.org\/10.1093\/brain\/awac333","journal-title":"Brain"},{"key":"2660_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Su\u00e1rez-Calvet M, Troakes C, King A, Emersic A et al (2020) Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 140:267\u2013278. https:\/\/doi.org\/10.1007\/s00401-020-02195-x","journal-title":"Acta Neuropathol"},{"key":"2660_CR14","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE et al (2021) Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med 13:e14022. https:\/\/doi.org\/10.15252\/emmm.202114022","journal-title":"EMBO Mol Med"},{"key":"2660_CR15","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E et al (2016) Plasma tau in Alzheimer disease. Neurology 87:1827\u20131835. https:\/\/doi.org\/10.1212\/WNL.0000000000003246","journal-title":"Neurology"},{"key":"2660_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/WAD.0000000000000380","volume":"34","author":"C Mock","year":"2020","unstructured":"Mock C, Teylan M, Beecham G, Besser L, Cairns NJ, Crary JF et al (2020) The utility of the national Alzheimer\u2019s coordinating center\u2019s database for the rapid assessment of evolving neuropathologic conditions. Alzheimer Dis Assoc Disord 34:105\u2013111. https:\/\/doi.org\/10.1097\/WAD.0000000000000380","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2660_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol 123:1\u201311. https:\/\/doi.org\/10.1007\/s00401-011-0910-3","journal-title":"Acta Neuropathol"},{"key":"2660_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00405-1","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya L, Benedet AL, Tissot C, Vrillon A, Ashton NJ, Brum WS et al (2023) Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat Aging. https:\/\/doi.org\/10.1038\/s43587-023-00405-1","journal-title":"Nat Aging"},{"key":"2660_CR19","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412\u20132414. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a","journal-title":"Neurology"},{"key":"2660_CR20","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1093\/brain\/awac175","volume":"145","author":"MS Morrison","year":"2022","unstructured":"Morrison MS, Aparicio HJ, Blennow K, Zetterberg H, Ashton NJ, Karikari TK et al (2022) Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer\u2019s disease neuropathology and regional tau at autopsy. Brain 145:3546\u20133557. https:\/\/doi.org\/10.1093\/brain\/awac175","journal-title":"Brain"},{"key":"2660_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E et al (2020) Discriminative accuracy of plasma phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA 324:772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"key":"2660_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Dage JL et al (2021) Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27:1034\u20131042. https:\/\/doi.org\/10.1038\/s41591-021-01348-z","journal-title":"Nat Med"},{"key":"2660_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3392","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S et al (2022) Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic alzheimer disease: a secondary analysis of the Trailblazer-ALZ randomized clinical trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392","journal-title":"JAMA Neurol"},{"key":"2660_CR24","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM et al (2023) Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med 15:e17123. https:\/\/doi.org\/10.15252\/emmm.202217123","journal-title":"EMBO Mol Med"},{"key":"2660_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02408-5","author":"DS Smirnov","year":"2022","unstructured":"Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simr\u00e9n J, Lantero-Rodriguez J et al (2022) Plasma biomarkers for Alzheimer\u2019s Disease in relation to neuropathology and cognitive change. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-022-02408-5","journal-title":"Acta Neuropathol"},{"key":"2660_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2020.05.011","volume":"94","author":"MA Sugarman","year":"2020","unstructured":"Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD et al (2020) A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer\u2019s disease. Neurobiol Aging 94:60\u201370. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.05.011","journal-title":"Neurobiol Aging"},{"key":"2660_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnmol.2014.00042","volume":"7","author":"S Tenreiro","year":"2014","unstructured":"Tenreiro S, Eckermann K, Outeiro TF (2014) Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci 7:42","journal-title":"Front Mol Neurosci"},{"key":"2660_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. The Lancet Neurol 21:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6","journal-title":"The Lancet Neurol"},{"key":"2660_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/00005072-199501000-00006","volume":"54","author":"JP Vonsattel","year":"1995","unstructured":"Vonsattel JP, Aizawa H, Ge P, DiFiglia M, McKee AC, MacDonald M et al (1995) An improved approach to prepare human brains for research. J Neuropathol Exp Neurol 54:42\u201356. https:\/\/doi.org\/10.1097\/00005072-199501000-00006","journal-title":"J Neuropathol Exp Neurol"},{"key":"2660_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00401-007-0311-9","volume":"115","author":"JP Vonsattel","year":"2008","unstructured":"Vonsattel JP, Del Amaya MP, Keller CE (2008) Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol 115:509\u2013532. https:\/\/doi.org\/10.1007\/s00401-007-0311-9","journal-title":"Acta Neuropathol"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-023-02660-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-023-02660-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-023-02660-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T17:01:50Z","timestamp":1703955710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-023-02660-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2660"],"URL":"https:\/\/doi.org\/10.1007\/s00401-023-02660-3","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,30]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. PRN participated in Advisory Board for Roche, Novo Nordics and Cerveau (outside submitted work). Andrew E. Budson has served on a consultant or on advisory boards for Sage Pharmaceuticals and Cognito Therapeutics and has received grant monies from Biogen, Bristol Myers Squibb, and Cyclerion. He receives publishing royalties from Elsevier and Oxford University Press. Rhoda Au serves on the scientific advisory board of Signant Health, as consultant to Biogen and has given a lecture in a symposia sponsored by Eisai. Robert A. Stern has served as a consultant to Biogen and Lundbeck. He receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. MLA has received honorarium from the Michael J Fox Foundation for services unrelated to this study. He also receives royalties from Oxford University Press. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"5"}}